Anorexia nervosa is a severe psychological disorder, and current treatment of anorexia nervosa relies on psychotherapy and medical nutritional support. The study applied food additives to the relevant treatment, aiming to help improve the patients’ diet.

Patients who met the diagnostic criteria of anorexia nervosa were randomly selected and divided into experimental and control groups, with 25 patients in each group. The experimental group received food additive-assisted treatment, while the control group received only conventional treatment. Before and after treatment, the patients’ body mass index (BMI) and height were measured, and eating disorders were assessed using the EDE-Q. The resultant data were analyzed using SPSS22.0.

After treatment, the BMI of the experimental group was significantly higher than that before treatment (F=18.42, P<0.05), while the BMI of the control group did not change significantly (F=9.71, P>0.05). In the EDE-Q scale assessment, the experimental group scored lower than the control group in terms of frequency of binge eating, frequency of emesis, and restriction of eating factor, and the difference was statistically significant (P<0.05).

After treatment, patients in the experimental group showed a significant increase in BMI, and the frequency of binge eating, frequency of emetic, and restriction of eating factor scores were lower than those of the control group. This suggests that food additives may have potential efficacy in alleviating the symptoms of anorexia nervosa.

Schizophrenia is a complex mental disorder with a chronic course. The atypical antipsychotics represented by lurasidone are commonly used in chronic schizophrenia, and its mechanism of action determines the superiority of efficacy and safety. However so far, there are still some adverse reactions, of which the more significant are lethargy, nausea, and sedentary inability. In view of these situations, we will combine nutrition intervention with the use of lurasidone to eliminate adverse reactions and provide help for the formulation of treatment plans.

The study will be based on whether to add nutrition intervention as a difference set up control experiment, the experimental group using lurasidone combined nutrition intervention, the control group using lurasidone single factor intervention. The patients who received treatment in the psychiatric department of our hospital from March 2021 to March 2022 were selected as the research objects, and the efficacy and adverse reactions of the patients were monitored during the treatment. The efficacy will be judged by the medical scale of symptom severity of patients with schizophrenia (Positive and Negative Syndrome Scale, PANSS) and the monitoring data will be statistically analyzed by SPSS.

With the treatment, the results of the Experimental group and the control group are shown in Table 1. The PANSS scores of the two groups finally reached a range of 30-40, with a difference of 4. The incidence of nausea, lethargy and sedentary disorder in adverse symptoms was higher in the control group, and the difference was statistically significant (P < 0.05). It shows that nutritional intervention cannot affect the efficacy of psychosis itself, yet can alleviate the adverse symptoms after medication.Table 1.

Efficacy and adverse reactions of the two groups

The group of schizophrenics is not limited to a certain age. Therefore, adverse symptoms caused by psychotropic drugs need to be considered in the practice. Symptoms in the course of the patient’s disease can be used as a treatment optimization path. Although the nutrition intervention strategy has no direct impact on the indicators of mental illness, the prevention of adverse symptoms during treatment can improve the actual experience of patients. In the future, the nutrition strategy will be adaptively optimized to improve the rehabilitation effect of chronic schizophrenia.

The research is supported by: Key Discipline of Nutrition and Food Hygiene of Changsha Medical university Quality Engineering Construction Project+2016; Study on Intervention Effect of Mindfulness Acceptance Stress Project on Nurses Aid to COVID-19+Outstanding Youth Project of Scientific Research of Hunan Education Department +2020(264)20B070.

The fast pace of modern life and work competition has led to an increase in the incidence rate of depression year by year. In recent years, Mongolian medicine has achieved good results in the treatment of depression. Research on the production of Mongolian medicine group based on Qiwei Guangzao pill to explore its therapeutic effect on moderate depression.

The study selected 70 patients with moderate depression and randomly divided them into an experimental group and a control group. The experimental group received Mongolian medicine based on Qiwei Guangzao pills in the morning, middle, and evening, supplemented by droperidol and melitracen tablets; The control group only received oral administration of flupentixol and melitracin tablets. The treatment course was 4 weeks, and the patient’s status was evaluated by Hamilton Depression Scale (HAMD) score. SPSS25.0 software was used for statistical analysis of the data obtained.

Compared to the control group, the rehabilitation rate of patients in the experimental group was 14.3%, and the proportion of patients with significant treatment effects was 45.8%. The total effective rate was about 91.4%, indicating that the improvement of HAMD scores in the experimental group was higher than that in the control group.

The experimental results show that the Mongolian medicine group based on Qiwei Guangzao pill has a significant therapeutic effect on moderate depression, and can effectively improve patients’ sleep status and gastrointestinal symptoms.

The National Natural Science Foundation of China, Correlational study on Lianqiao-4 and intestinal flora in the treatment of liver injury by the theory of “ essence and dross decomposition” (Grant No. 82060910); The National Natural Science Foundation for Young Scientists of China, Study on genomics and proteomics mechanism of Lianqiao-4 against liver injury based on the theory of “ essence and dross decomposition “ in Mongolian Medicine (Grant No. 81760765); The central government supported cross-disciplinary projects with special funds for local construction (No. JCHXKXM001).

COVID-19 is highly contagious, which has a significant impact on people’s physical health and mental health. Under the current COVID-19, some people have negative emotions, such as anger and fear, which have triggered psychological stress, resulting in acute stress disorder of different degrees. Therefore, the study put forward a targeted clinical medication scheme. It applies corresponding nursing measures to explore the role of the targeted medication scheme in improving the mental health and the life quality of patients.

Among the patients with acute stress disorder admitted to our hospital from June 2020 to July 2021, 80 patients with delirium caused by the COVID-19 were selected as research objects according to the medical records and disease analysis. Before using the new clinical medication scheme and nursing measures for treatment, the patients’ delirium and stress disorder were evaluated by Stanford Acute Stress Response Questionnaire (SASRQ) and 3-min Confusion Assessment Scale (3D-CAM). Then the new clinical medication scheme and nursing measures was applied for four weeks, including specific medication for acute stress disorder and delirium, and evaluate the disease status again with the two selected scales.

Table 1 shows the results of SASRQ score and 3D-CAM score of 80 selected patients before and after treatment. The results showed that before treatment, both the SASRQ score and the 3D-CAM score showed that the patient had different degrees of delirium and acute stress disorder. After treatment, both the 3D-CAM score and the SASRQ score of the patient decreased significantly, and the symptoms of acute stress disorder complicated with delirium were significantly improved, with a statistically significant difference (P < 0.05).Table 1.

Results of SASRQ score and 3D-CAM score of 80 patients before and after treatment

Under the COVID-19, some people suffer from acute stress disorder and delirium. Therefore, the study put forward a specific clinical medication scheme and nursing measures for these patients, and assessed the acute stress disorder and delirium status before and after treatment through SASRQ and 3D-CAM scales. The results verified the effectiveness of the medication scheme, which had certain clinical application value.

The form of group training for prisoners near the end of their prison sentence are often taken in China to help them enhance their ability to adapt to the society after being released from prison, but this training may have shortcomings of weak pertinence and non-differentiation. A prisoner had turned to his supervisor for help due to the emotional anxiety two months before the end of his prison sentence, which caused the concern to the individual psychological state of the prisoner. In order to reduce the stress and abnormal psychological state of prisoners before their release, and help them to rebuild themselves after returning to society, psychological tests and questionnaires were conducted on prisoners whose remaining prison term was less than three months. The prisoners with psychological fluctuations were screened out for timely intervention.

A prisoner, 23-year-old, male, complained of inattention, depression, tension, irritability and frequent insomnia, this phenomenon has been interrupted for a month. So, two months before his release from prison, he sought help from the prison Psychological Counseling Department. The psychological test result of the man is as follows: The Self Rating Anxiety Scale test (SAS) result is 67 points, which is higher than the norm, and SCL-90 Self-Rating Depression Scale (SCL-90) anxiety factor 2.6, higher than the norm. Through the use of cognitive therapy and relaxation training by the counselors, there was no anxiety state in the psychological test after four psychological consultations. The case aroused the concern about the psychological state of the criminals before their release from prison, and 30 criminals with the three months remaining in prison were given psychological tests and questionnaires to understand their psychological state. The questionnaire was conducted by self- filling method, the main contents included: criminal history, prison experience, self-evaluation of psychological state, planning after being released from prison, etc. The 30 criminals participated in SCL-90 test to understand their psychological status.

Among the 30 prisoners who participated in the SCL-90 test, 8 had higher anxiety factors than the norm, and 6 of them were under the age of 35. According to the statistics of the questionnaire survey results of 30 prisoners near the end of their sentence, 25 people felt that their recent sleep status was average or poor; 20 people have no desire to talk with others and discuss the future. 16 people did not have any life plans after releasing from prison. Among the 30 prisoners who participated in the questionnaire survey, 10 hoped to get pre-release employment guidance from the prison, and 10 hoped to participate in classes to learn skills such as reading clubs, computer or finance courses organized by the prison.

Prisoners before their release, especially young prisoners under 35 years old, are more likely to have anxiety or irritability. Although the number of prisoners who are troubled with this psychological state and ask for help from supervisors is not large, and the number who take the initiative to plan their life before they are released from prison is also not large, most prisoners still hope to get care and help from the prison in their future life or have a job before they leave prison. Therefore, it is very important to pay more attention to the psychology of pre-release prisoners, especially the young people.

Acute Respiratory Distress Syndrome (ARDS) is a severe lung disease, and its condition can lead to depressive disorders in patients. Understanding the subjective sleep quality of ARDS patients with depressive disorder conditions and their influencing factors is essential for developing effective interventions and improving patients’ sleep quality.

Sixty patients with depression were selected as the study subjects and randomly divided into experimental and control groups, with 30 people in each group. Pittsburgh Sleep Quality Index (PSQI), Symptom Checklist-90 (SCL-90), Self-Rating Anxiety Scale (SAS), Social Desirability Scale (SDS), State-Trait Anxiety Inventory (STAI), Life Event Scale (LES), and SQL Server Reporting Services (SSRS) were used for assessment. The data collected were analyzed by the relationship between PSQI and the results of the other six rating scales using SPSS23.0.

Sleep disorders were found in 77.8% of 60 patients with depression. The total score and factors of PSQI were significantly correlated with SCL-90 somatization, obsessive-compulsive disorder, depression, anxiety, and total mean score (P<0.05). The PSQI was positively correlated with SAI in SAS and STAI (P<0.01) but not correlated with TAI in STAI (P>0.05). The somatization disorder factor in SDS was significantly correlated with the PSQI factors and total scores except for the sleep persistence factor (P<0.05). The daytime dysfunction factor in PSQI was significantly correlated with the full score of social support (P<0.05), whereas there was no significant correlation between PSQI and LES (P>0.05).

Depressive disorders in ARDS patients hurt their subjective sleep quality.